COVID-19 Clinical Trial
Official title:
Effects of Prompt to Bundle COVID-19 Booster and Flu Shot
This randomized controlled trial investigates whether text-based reminders can increase the bivalent COVID-19 booster uptake and whether text-based reminders that mention the opportunity to bundle the COVID-19 booster with the flu shot within the same appointment can increase take-up of both the COVID-19 booster and the flu vaccine.
Status | Recruiting |
Enrollment | 97000 |
Est. completion date | December 31, 2023 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients aged 18 or above - Have a mobile phone number or SMS-capable phone number in UCLA Health's database - Having completed a COVID-19 vaccine primary series based on CAIR data - Last COVID-19 vaccine shot (including booster shot) occurred at least two months before the date when patient list are pulled in preparation for the trial, based on CAIR data. The last two criteria meant to identify patients who are eligible for the updated booster. Exclusion Criteria: - Patients who have received the bivalent booster anywhere (based on CAIR data) before the day they receive the text message - Patients who have already scheduled appointments at UCLA Health for getting the bivalent booster before the day they receive the text message |
Country | Name | City | State |
---|---|---|---|
United States | UCLA Health Department of Medicine, Quality Office | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Los Angeles |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | booster take-up at UCLA/CVS in 2 weeks | Whether people receive the bivalent booster at either UCLA Health or CVS Pharmacy | 2 weeks after getting the text message | |
Primary | booster take-up at UCLA/CVS in 4 weeks | Whether people receive the bivalent booster at either UCLA Health or CVS Pharmacy | 4 week after getting the text message | |
Secondary | Link click rate in 1 week | Whether people click on at least one link provided in the text message | 1 week after getting the text message | |
Secondary | booster take-up in 2 weeks | Whether people receive the bivalent booster at any location reporting to the California Immunization Registry (CAIR) | 2 weeks after getting the text message | |
Secondary | booster take-up in 4 weeks | Whether people receive the bivalent booster at any location reporting to the California Immunization Registry (CAIR) | 4 weeks after getting the text message | |
Secondary | Flu vaccine take-up at UCLA/CVS in 2 weeks | Whether people receive the flu vaccine at either UCLA Health or CVS Pharmacy | 2 weeks after getting the text message | |
Secondary | Flu vaccine take-up at UCLA/CVS in 4 weeks | Whether people receive the flu vaccine at either UCLA Health or CVS Pharmacy | 4 weeks after getting the text message | |
Secondary | Flu vaccine take-up in 2 weeks | Whether people receive the flu vaccine at at any location reporting to the California Immunization Registry (CAIR) | 2 week after getting the text message | |
Secondary | Flu vaccine take-up in 4 weeks | Whether people receive the flu vaccine at any location reporting to the California Immunization Registry (CAIR) | 4 weeks after getting the text message |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|